佛慈制药
(002644)
| 流通市值：40.34亿 | | | 总市值：40.34亿 |
| 流通股本：5.11亿 | | | 总股本：5.11亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 211,574,701.05 | 915,533,598.79 | 624,055,200.7 | 429,365,466.8 |
| 营业收入 | 211,574,701.05 | 915,533,598.79 | 624,055,200.7 | 429,365,466.8 |
| 二、营业总成本 | 183,095,248.39 | 813,851,221.73 | 564,312,051.85 | 380,743,426.65 |
| 营业成本 | 133,022,807.41 | 603,416,413.47 | 418,622,128.29 | 283,945,418.43 |
| 税金及附加 | 3,395,052.25 | 15,569,775.55 | 10,851,900.11 | 7,297,901.64 |
| 销售费用 | 25,448,178.66 | 102,357,944.28 | 72,223,250.25 | 46,903,224.22 |
| 管理费用 | 17,697,049.71 | 72,856,748.17 | 47,148,064.22 | 31,729,859.9 |
| 研发费用 | 4,755,874.56 | 24,555,383.4 | 18,073,933.17 | 13,281,225.46 |
| 财务费用 | -1,223,714.2 | -4,905,043.14 | -2,607,224.19 | -2,414,203 |
| 其中:利息费用 | - | 770,722.73 | 1,681,584.62 | 378,448.66 |
| 其中:利息收入 | - | 5,897,953.91 | 4,286,751.49 | 2,831,725.28 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -2,020,001.15 | -13,537,423.9 | -5,614,526.6 | -3,921,948.13 |
| 资产处置收益 | 0 | 7,131,603.77 | 1,415.92 | 1,415.92 |
| 资产减值损失(新) | - | -1,793,611.93 | - | - |
| 信用减值损失(新) | -4,835,911.52 | -56,646,435.06 | -28,861,144.13 | -21,479,697.36 |
| 其他收益 | 5,501,440.35 | 29,148,994.55 | 18,314,145.48 | 11,384,545.76 |
| 四、营业利润 | 27,124,980.34 | 65,985,504.49 | 43,583,039.52 | 34,606,356.34 |
| 加:营业外收入 | 10,972.83 | 829,998.65 | 429,246.1 | 1,322,171.77 |
| 减:营业外支出 | 103,055.95 | 1,785,074.13 | 1,736,405.4 | 1,289,781.43 |
| 五、利润总额 | 27,032,897.22 | 65,030,429.01 | 42,275,880.22 | 34,638,746.68 |
| 减:所得税费用 | 4,161,283.51 | 18,075,412.57 | 5,131,118.49 | 4,692,312.26 |
| 六、净利润 | 22,871,613.71 | 46,955,016.44 | 37,144,761.73 | 29,946,434.42 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 22,871,613.71 | 46,955,016.44 | 37,144,761.73 | 29,946,434.42 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 22,661,247.41 | 49,207,166.39 | 38,082,371.36 | 30,104,611.31 |
| 少数股东损益 | 210,366.3 | -2,252,149.95 | -937,609.63 | -158,176.89 |
| 扣除非经常损益后的净利润 | 18,056,674.65 | 20,239,831.89 | 23,809,045.68 | 20,850,937.98 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.1 | 0.07 | 0.06 |
| (二)稀释每股收益 | 0.04 | 0.1 | 0.07 | 0.06 |
| 八、其他综合收益 | - | -90,160.47 | 43,576.26 | 43,576.26 |
| 归属于母公司股东的其他综合收益 | - | -46,488.99 | 22,469.01 | 22,469.01 |
| 九、综合收益总额 | 22,871,613.71 | 46,864,855.97 | 37,188,337.99 | 29,990,010.68 |
| 归属于母公司股东的综合收益总额 | 22,661,247.41 | 49,160,677.4 | 38,104,840.37 | 30,127,080.32 |
| 归属于少数股东的综合收益总额 | 210,366.3 | -2,295,821.43 | -916,502.38 | -137,069.64 |
| 公告日期 | 2026-04-30 | 2026-04-09 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |